Braveheart's HRS/BHB-1893 Holds 52-Week Benefit; Fixed-Dose Phase 2b TRUEHEART-HCM Planned
BRVE is trading near its 52-week low of $16.7 (9.6% above the low).
Summary
Braveheart presented 52-week open-label extension data at AHA showing durable exercise-capacity and symptom gains and deep LVOT gradient reduction with HRS/BHB-1893, with most patients staying on the starting dose. The company also outlined a planned fixed-dose Phase 2b oHCM study, TRUEHEART-HCM.
Key Events · Product Development and Regulatory · BRVE
-
52-Week OLE Data Show Durable Benefit
At Week 52 of the open-label extension, mean pVO2 rose 2.7 mL/kg/min and KCCQ-CSS rose 17.3 points from OLE baseline; 79% (33/42) achieved Valsalva LVOT-G below 30 mmHg.
-
Majority Stay on Starting Dose
57% (24/42) of patients ended the study on the 40 mg BID starting dose and 19% (8/42) on 60 mg BID, supporting a simplified, lower-monitoring regimen.
-
Clean Long-Term Safety Profile
No on-treatment severe or serious adverse events over 52 weeks; all TEAEs were mild or moderate and none led to discontinuation, with two transient LVEF reductions below 50% (48% and 49%) that resumed at a lower dose.
-
Fixed-Dose Phase 2b TRUEHEART-HCM Planned
Braveheart said the data inform future clinical plans, including a planned fixed-dose Phase 2b study in oHCM (TRUEHEART-HCM), discussed on a same-day investor webcast.
Analysis · BRVE · Life Sciences
The 52-week open-label extension shows the effect holding up rather than fading: mean pVO2 up 2.7 mL/kg/min and KCCQ-CSS up 17.3 points from OLE baseline, with 79% of patients (33/42) below the 30 mmHg Valsalva gradient threshold at Week 52. Just as important commercially, 57% of patients stayed on the 40 mg BID starting dose, which supports a simpler, lower-monitoring regimen than rival cardiac myosin inhibitors — the basis for the planned fixed-dose Phase 2b TRUEHEART-HCM study. Safety was clean over the year (no severe or serious on-treatment events; two transient LVEF dips that resolved on a lower dose). For a clinical-stage company whose entire valuation rests on this asset, durable efficacy plus a dosing advantage is the core thesis evidence, and the nHCM diastolic data open a second, roughly one-third of the HCM population.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRVE was trading at $18.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $16.70 to $32.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.